General, 131 infants died before 36 weeks of postmenstrual age, and 239 infants were categorized as having bronchopulmonary dysplasia. In 52 of the infants with bronchopulmonary dysplasia in the budesonide group and 46.3 percent in the placebo group . In a secondary analysis that included adjustment for other covariates, the odds ratio for the primary outcome in the budesonide group, in comparison with the placebo group, was 0.71 . The treatment effect was not significantly influenced by intubation status, gestational age, or the presence or absence of chorioamnionitis . The net treatment effect on the composite outcome was explained by a reduction in the incidence of bronchopulmonary dysplasia. A analysis of bronchopulmonary dysplasia was manufactured in 101 of the 363 infants assigned to budesonide who were alive at a postmenstrual age group of 36 weeks, as compared with 138 of the 363 infants assigned to placebo .Within this model, there are additional community-supported interventions, such as emergency transportation, in addition to orientation for both community and professionals. The scheduled program reinforces principal safe motherhood text messages and a straightforward system of monitoring pregnancy outcomes. The facility-based Life Keeping Abilities training enhances the capacity for emergency obstetric care. Only following the entire continuum of care is strengthened will generally there impact on neonatal and maternal morbidity and mortality.